| Trial registration number
|
NCT05672888 |
Full text link
Last imported at : Jan. 6, 2023, 8 p.m.
Source : ClinicalTrials.gov
|
https://clinicaltrials.gov/show/NCT05672888
|
First author
Last imported at : Jan. 6, 2023, 8 p.m.
Source : ClinicalTrials.gov
|
Jianya Zhou
|
Contact
Last imported at : Jan. 6, 2023, 8 p.m.
Source : ClinicalTrials.gov
|
zhoujianya@hotmail.com
|
Registration date
Last imported at : Jan. 6, 2023, 8 p.m.
Source : ClinicalTrials.gov
|
2023-01-05
|
Recruitment status
Last imported at : Jan. 6, 2023, 8 p.m.
Source : ClinicalTrials.gov
|
Not recruiting
|
Study design
Last imported at : Jan. 6, 2023, 8 p.m.
Source : ClinicalTrials.gov
|
RCT
|
Allocation
Last imported at : Jan. 6, 2023, 8 p.m.
Source : ClinicalTrials.gov
|
Randomized
|
Design
Last imported at : Jan. 6, 2023, 8 p.m.
Source : ClinicalTrials.gov
|
Parallel
|
Masking
Last imported at : Jan. 6, 2023, 8 p.m.
Source : ClinicalTrials.gov
|
Blind label
|
Center
Last imported at : March 15, 2023, 4 a.m.
Source : ClinicalTrials.gov
|
single-center
|
Study aim
Last imported at : Jan. 6, 2023, 8 p.m.
Source : ClinicalTrials.gov
|
Treatment
|
Inclusion criteria
Last imported at : Jan. 6, 2023, 8 p.m.
Source : ClinicalTrials.gov
|
inclusion criteria:
18 years of age, male or female;
history of covid-19 infection within 1 week;
subjects with hrct consistent with viral pneumonia (judged by investigator) and meeting any of the following criteria: with fever, respiratory symptoms; shortness of breath present,rr ≥30 breaths/min.
clear consciousness, capable and voluntary informed consent.
|
Exclusion criteria
Last imported at : Jan. 6, 2023, 8 p.m.
Source : ClinicalTrials.gov
|
unable to take tablets orally or suspected hypersensitivity to jaktinib, drugs of the same class, or their excipients, patients with severe gastrointestinal dysfunction affecting drug absorption;
any person meeting criteria for critical pneumonia;
patients considered unsuitable for this trial by the investigator.
|
Number of arms
Last imported at : Jan. 6, 2023, 8 p.m.
Source : ClinicalTrials.gov
|
2
|
Funding
Last imported at : Jan. 6, 2023, 8 p.m.
Source : ClinicalTrials.gov
|
First Affiliated Hospital of Zhejiang University
|
Inclusion age min
Last imported at : Jan. 6, 2023, 8 p.m.
Source : ClinicalTrials.gov
|
18
|
Inclusion age max
Last imported at : Jan. 6, 2023, 8 p.m.
Source : ClinicalTrials.gov
|
100
|
Countries
Last imported at : Jan. 6, 2023, 8 p.m.
Source : ClinicalTrials.gov
|
China
|
Type of patients
Last imported at : Jan. 6, 2023, 8 p.m.
Source : ClinicalTrials.gov
|
Moderate/severe disease at enrollment
|
Severity scale
Last imported at : Jan. 6, 2023, 8 p.m.
Source : ClinicalTrials.gov
|
4: Moderate/severe disease at enrollment
|
Total sample size
Last imported at : Jan. 6, 2023, 8 p.m.
Source : ClinicalTrials.gov
|
60
|
primary outcome
Last imported at : Jan. 6, 2023, 8 p.m.
Source : ClinicalTrials.gov
|
Time to Recovery
|
Notes
Last imported at : Jan. 6, 2023, 8 p.m.
Source : ClinicalTrials.gov
|
None
|
Phase
Last imported at : Jan. 6, 2023, 8 p.m.
Source : ClinicalTrials.gov
|
Phase 2
|
Arms
Last imported at : Jan. 6, 2023, 8 p.m.
Source : ClinicalTrials.gov
|
[{"arm_notes": "nan", "treatment_id": 2679, "treatment_name": "Jaktinib", "treatment_type": "Kinase inhibitors", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "nan", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]
|